We have located open access text paper links.
Safety and tolerability of sodium glucose cotransporter-2 inhibitors in children and young adults: A systematic review and meta-analysis.
Annals of Pediatric Endocrinology & Metabolism 2024 January 3
PURPOSE: Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been evaluated in children with type-2 diabetes (T2DM), Type-1 diabetes (T1DM) and several other non-diabetic conditions. Potential tolerability issues have been preventing us from routinely using SGLT2i in children with diabetes. No meta-analysis till date has evaluated the safety and tolerability of SGLT2i in children. This systematic review and meta-analysis aimed to address this knowledge-gap.
METHODS: Databases were searched for randomized controlled trials (RCTs), case-control and cohort studies involving children receiving SGLT2i in intervention-arm. Primary outcome was occurrence of treatment-emergent adverse events (TAEs). Secondary outcomes were evaluation of glycaemic efficacy and occurrence of severe adverse-events (SAEs), hypoglycaemia, ketosis, genital or urinary infections and any other adverse-events.
RESULTS: From initially screened 27 articles, data from 4 RCT (258 children) was analyzed. In children with T2DM, occurrence of TAEs [OR 1.77(95%CI:0.93-3.36);P=0.08;I2=0%], SAEs [OR 0.45(95%CI:0.08-2.54);P=0.37;I2=0%], ketoacidosis [OR 0.33(95%CI:0.01-8.37);P=0.50], urinary tract infections [OR 2.34(95%CI:0.44-12.50);P=0.32;I2=0%] and severe hypoglycaemia [OR 4.47(95%CI:0.21-96.40);P=0.34] were comparable among SGLTi group and placebo. Compared to placebo, T2DM children receiving SGLTi had significantly lower HbA1C at 24-26 weeks [MD -0.79%(95%CI:-1.33--0.26);P=0.004;I2=0%]. In T1DM children, ß-hydroxybutyrate levels were significantly higher in SGLTi group compared to placebo [MD 0.11mmol/L(95%CI:0.05-0.17);P=0.0005;I2=53%]. In T1DM, there was not a single report of SAE, ketoacidosis, severe hypoglycaemia among both groups, with time in range considerably greater in SGLT2i group (68%±6% vs. 50%±13%;P<0.001).
CONCLUSION: This study provides us with reassuring data on safety of use of SGLT2i in children and young adults.
METHODS: Databases were searched for randomized controlled trials (RCTs), case-control and cohort studies involving children receiving SGLT2i in intervention-arm. Primary outcome was occurrence of treatment-emergent adverse events (TAEs). Secondary outcomes were evaluation of glycaemic efficacy and occurrence of severe adverse-events (SAEs), hypoglycaemia, ketosis, genital or urinary infections and any other adverse-events.
RESULTS: From initially screened 27 articles, data from 4 RCT (258 children) was analyzed. In children with T2DM, occurrence of TAEs [OR 1.77(95%CI:0.93-3.36);P=0.08;I2=0%], SAEs [OR 0.45(95%CI:0.08-2.54);P=0.37;I2=0%], ketoacidosis [OR 0.33(95%CI:0.01-8.37);P=0.50], urinary tract infections [OR 2.34(95%CI:0.44-12.50);P=0.32;I2=0%] and severe hypoglycaemia [OR 4.47(95%CI:0.21-96.40);P=0.34] were comparable among SGLTi group and placebo. Compared to placebo, T2DM children receiving SGLTi had significantly lower HbA1C at 24-26 weeks [MD -0.79%(95%CI:-1.33--0.26);P=0.004;I2=0%]. In T1DM children, ß-hydroxybutyrate levels were significantly higher in SGLTi group compared to placebo [MD 0.11mmol/L(95%CI:0.05-0.17);P=0.0005;I2=53%]. In T1DM, there was not a single report of SAE, ketoacidosis, severe hypoglycaemia among both groups, with time in range considerably greater in SGLT2i group (68%±6% vs. 50%±13%;P<0.001).
CONCLUSION: This study provides us with reassuring data on safety of use of SGLT2i in children and young adults.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app